Latest data from the Phase 3 PALISADE trial of plozasiran in familial chylomicronaemia syndrome (FCS) have demonstrated quality of life (QoL) improvements associated with previously reported reductions in TG and acute pancreatitis (AP).
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
